FMO5 and inflammatory bowel disease: An increase in the expression of NADPH oxidase and NOS and their RONS products has been observed in various types of cancer and chronic inflammatory diseases, such as H. pylori-associated gastritis and inflammatory bowel diseases (IBD), suggesting a role in genesis and malignant progression [21].